Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.43 |
| ▸ | WNT3A | P56704 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051449 | 0.86 | DYRK1A (0.55) | ALDH1A1MEN1KMT2AGAACYP2A6 | |
| SCHEMBL3582670 | 0.85 | DYRK1A (0.45) | ALDH1A1MEN1KMT2AGAACYP2A6 | |
| SCHEMBL27130686 | 0.82 | DYRK1A (0.46) | ALDH1A1MEN1KMT2AGAADYRK1A | |
| SCHEMBL27610665 | 0.81 | MEN1 (0.45) | ALDH1A1MEN1KMT2AGAACYP2A6 | |
| SCHEMBL5539641 | 0.81 | DYRK1A (0.45) | ALDH1A1MEN1KMT2AGAADYRK1A | |
| SCHEMBL15969643 | 0.81 | DYRK1A (0.45) | ALDH1A1MEN1KMT2AGAADYRK1A | |
| SCHEMBL3931160 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ADYRK1ACTNNB1 | |
| SCHEMBL11869172 | 0.76 | ESR1 (0.60) | ALDH1A1MEN1KMT2AGAACTNNB1 | |
| SCHEMBL2110106 | 0.75 | FBP1 (0.49) | ALDH1A1RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL13500881 | 0.74 | MEN1 (0.61) | ALDH1A1MEN1KMT2AGAADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0180813-B1 | CHROMOGENIC 4,4-DIARYLDIHYDROCHINAZOLONES, THEIR PREPARATION AND USE | BAYER AG (DE) | 1988-06-01 | — | — | EP | claimed |
| EP-0180813-A1 | Chromogenic 4,4-diaryldihydrochinazolones, their preparation and use | BAYER AG (DE) | 1986-05-14 | — | — | EP | claimed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250361238-A1 | 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | SOPONPONG JAKAPUN (TH) | 2025-11-27 | — | — | US | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| CN-114828959-B | 3- (5-methoxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof | 诺华股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-110582493-B | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4076650-B1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| EP-4076650-B1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-117177969-A | Compound with benzyloxy aryl ether structure, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-12-05 | — | — | CN | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| CN-102245605-A | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections | ASTRAZENECA AB | 2011-11-16 | — | — | CN | disclosed |
| US-6921821-B2 | Antagonists of melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1534703-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | ABBOTT LABORATORIES (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2003106452-A2 | ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-6589915-B1 | The invention relates to cyclohexenone derivatives of benzo-condensed, unsaturated 5-ring nitrogen heterocycles of general formula (I) wherein X represents N or a group C-R3, Y represents O, S, SO, SO2 or NR4 or X-Y represent S | BASF AKTIENGESELLSCHAFT (DE) | 2003-07-08 | — | — | US | disclosed |
| US-6541423-B1 | Controlling vegatation | BASF AKTIENGESELLSCHAFT (DE) | 2003-04-01 | — | — | US | disclosed |
| EP-0180813-B1 | CHROMOGENIC 4,4-DIARYLDIHYDROCHINAZOLONES, THEIR PREPARATION AND USE | BAYER AG (DE) | 1988-06-01 | — | — | EP | disclosed |
| EP-0180813-A1 | Chromogenic 4,4-diaryldihydrochinazolones, their preparation and use | BAYER AG (DE) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | ALDH1A1 3506/4885MEN1 3901/4885KMT2A 3663/4885 |
| US-20250361238-A1 | 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | PDCD1, CD274, PDCD1LG2 | ALDH1A1 36/4885MEN1 2605/4885KMT2A 2449/4885 |
| US-20040106645-A1 | Antagonists of melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | ALDH1A1 660/4885MEN1 633/4885KMT2A 1796/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | ALDH1A1 3735/4885MEN1 1550/4885KMT2A 2363/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | ALDH1A1 4369/4885MEN1 2/4885KMT2A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.